Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THN391 in Diabetic Macular Edema
NCT06701721Phase 1Recruiting
- Sponsor
- Therini Bio
- Start
- Dec 2024
- Primary completion
- Mar 2027
- Modality
- IgG Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of THN391 in diabetic macular edema (DME) (3 cohorts), sponsored by Therini Bio. Primary endpoint: Adverse Events at 16 weeks. Started Dec 2024; status: recruiting.
02
Drugs
THN391
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06701721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06701721.